195 related articles for article (PubMed ID: 35364770)
21. Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series.
Kang SA; Sweeney M; Govindarajan R
J Clin Neuromuscul Dis; 2022 Jun; 23(4):210-218. PubMed ID: 35608645
[TBL] [Abstract][Full Text] [Related]
22. Cellular changes in eculizumab early responders with generalized myasthenia gravis.
Li Y; Yi JS; Howard JF; Chopra M; Russo MA; Guptill JT
Clin Immunol; 2021 Oct; 231():108830. PubMed ID: 34450290
[TBL] [Abstract][Full Text] [Related]
23. Complement Inhibitor Therapy for Myasthenia Gravis.
Albazli K; Kaminski HJ; Howard JF
Front Immunol; 2020; 11():917. PubMed ID: 32582144
[TBL] [Abstract][Full Text] [Related]
24. [Eculizumab led to beneficial clinical course in a patient with generalized myasthenia gravis who developed COVID 19-associated pneumonia].
Kuroda Y; Watanabe G; Satou K; Ono H; Tsukita K; Suzuki Y
Rinsho Shinkeigaku; 2024 Feb; 64(2):109-112. PubMed ID: 38281749
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
[TBL] [Abstract][Full Text] [Related]
27. Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
Uzawa A; Ozawa Y; Yasuda M; Kuwabara S
J Neuroimmunol; 2020 Dec; 349():577424. PubMed ID: 33068973
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
[TBL] [Abstract][Full Text] [Related]
29. Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
Zadeh S; Price H; Drews R; Bouffard MA; Young LH; Narayanaswami P
Muscle Nerve; 2024 Mar; 69(3):368-372. PubMed ID: 38205840
[TBL] [Abstract][Full Text] [Related]
30. Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series.
Levine TD
Am J Case Rep; 2019 Jul; 20():965-970. PubMed ID: 31278249
[TBL] [Abstract][Full Text] [Related]
31. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
Beecher G; Putko BN; Wagner AN; Siddiqi ZA
Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
[TBL] [Abstract][Full Text] [Related]
32. Minimal Manifestations With Eculizumab Therapy in a Patient With Refractory Generalized Seropositive Myasthenia Gravis.
Abdulrazaq A; Smith R; Digala LP; Govindarajan R
J Clin Neuromuscul Dis; 2022 Mar; 23(3):170-173. PubMed ID: 35188923
[No Abstract] [Full Text] [Related]
33. Myasthenia gravis: the role of complement at the neuromuscular junction.
Howard JF
Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
[TBL] [Abstract][Full Text] [Related]
34. Eculizumab improves fatigue in refractory generalized myasthenia gravis.
Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF;
Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021
[TBL] [Abstract][Full Text] [Related]
35. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.
Kim MS; Prasad V
JAMA Intern Med; 2020 Feb; 180(2):315-317. PubMed ID: 31657842
[TBL] [Abstract][Full Text] [Related]
36. Myasthenia gravis: State of the art and new therapeutic strategies.
Souto EB; Lima B; Campos JR; Martins-Gomes C; Souto SB; Silva AM
J Neuroimmunol; 2019 Dec; 337():577080. PubMed ID: 31670062
[TBL] [Abstract][Full Text] [Related]
37. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
Siddiqi ZA; Nowak RJ; Mozaffar T; O'Brien F; Yountz M; Patti F;
Muscle Nerve; 2021 Dec; 64(6):662-669. PubMed ID: 34590717
[TBL] [Abstract][Full Text] [Related]
38. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
Patriquin CJ; Kuo KHM
Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
[TBL] [Abstract][Full Text] [Related]
39. Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Suh J; Clarke V; Amato AA; Guidon AC
Muscle Nerve; 2022 Sep; 66(3):348-353. PubMed ID: 35684980
[TBL] [Abstract][Full Text] [Related]
40. The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis.
Tice JA; Touchette DR; Lien PW; Agboola F; Nikitin D; Pearson SD
J Manag Care Spec Pharm; 2022 Jan; 28(1):119-124. PubMed ID: 34949112
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
